Bone mineral density and explanatory factors in children and adults with juvenile dermatomyositis at long term follow-up; a cross sectional study.
Bone mineral density
DXA
IP-10
Inflammatory markers
Juvenile dermatomyositis
Prednisolone
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
26 Apr 2021
26 Apr 2021
Historique:
received:
13
11
2020
accepted:
14
04
2021
entrez:
27
4
2021
pubmed:
28
4
2021
medline:
25
11
2021
Statut:
epublish
Résumé
Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children and adolescents. Both the disease and its treatment with glucocorticoids may negatively impact bone formation. In this study we compare BMD in patients (children/adolescence and adults) with long-standing JDM with matched controls; and in patients, explore how general/disease characteristics and bone turnover markers are associated with BMD. JDM patients (n = 59) were examined median 16.8y (range 6.6-27.0y) after disease onset and compared with 59 age/sex-matched controls. Dual-energy X-ray absorptiometry (DXA) was used to measure BMD of the whole body and lumbar spine (spine) in all participants, and of ultra-distal radius, forearm and total hip in participants ≥20y only. Markers of bone turnover were analysed, and associations with outcomes explored. Reduced BMD Z-scores (<-1SD) were found in 19 and 29% of patients and 7 and 9% of controls in whole body and spine, respectively (p-values < 0.05). BMD and BMD Z-scores for whole body and spine were lower in all patients and for < 20y compared with their respective controls. In participants ≥20y, only BMD and BMD Z-score of forearm were lower in the patients versus controls. In patients, BMD Z-scores for whole body and/or spine were found to correlate negatively with prednisolone use at follow-up (yes/no) (age < 20y), inflammatory markers (age ≥ 20y) and levels of interferon gamma-induced protein 10 (IP-10) (both age groups). In all patients, prednisolone use at follow-up (yes/no) and age ≥ 20y were independent correlates of lower BMD Z-scores for whole body and spine, respectively. In long-term JDM, children have more impairment of BMD than adults in spine and whole-body. Associations with BMD were found for both prednisolone and inflammatory markers, and a novel association was discovered with the biomarker of JDM activity, IP-10.
Sections du résumé
BACKGROUND
BACKGROUND
Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children and adolescents. Both the disease and its treatment with glucocorticoids may negatively impact bone formation. In this study we compare BMD in patients (children/adolescence and adults) with long-standing JDM with matched controls; and in patients, explore how general/disease characteristics and bone turnover markers are associated with BMD.
METHODS
METHODS
JDM patients (n = 59) were examined median 16.8y (range 6.6-27.0y) after disease onset and compared with 59 age/sex-matched controls. Dual-energy X-ray absorptiometry (DXA) was used to measure BMD of the whole body and lumbar spine (spine) in all participants, and of ultra-distal radius, forearm and total hip in participants ≥20y only. Markers of bone turnover were analysed, and associations with outcomes explored.
RESULTS
RESULTS
Reduced BMD Z-scores (<-1SD) were found in 19 and 29% of patients and 7 and 9% of controls in whole body and spine, respectively (p-values < 0.05). BMD and BMD Z-scores for whole body and spine were lower in all patients and for < 20y compared with their respective controls. In participants ≥20y, only BMD and BMD Z-score of forearm were lower in the patients versus controls. In patients, BMD Z-scores for whole body and/or spine were found to correlate negatively with prednisolone use at follow-up (yes/no) (age < 20y), inflammatory markers (age ≥ 20y) and levels of interferon gamma-induced protein 10 (IP-10) (both age groups). In all patients, prednisolone use at follow-up (yes/no) and age ≥ 20y were independent correlates of lower BMD Z-scores for whole body and spine, respectively.
CONCLUSION
CONCLUSIONS
In long-term JDM, children have more impairment of BMD than adults in spine and whole-body. Associations with BMD were found for both prednisolone and inflammatory markers, and a novel association was discovered with the biomarker of JDM activity, IP-10.
Identifiants
pubmed: 33902632
doi: 10.1186/s12969-021-00543-z
pii: 10.1186/s12969-021-00543-z
pmc: PMC8077908
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
56Références
Aust Prescr. 2015 Jun;38(3):93-4
pubmed: 26648629
JAMA Netw Open. 2019 Aug 2;2(8):e198918
pubmed: 31397863
Clin Rheumatol. 2018 Aug;37(8):2169-2178
pubmed: 28551822
Clin Chem Lab Med. 2011 Aug;49(8):1271-4
pubmed: 21605012
J Clin Endocrinol Metab. 2015 Apr;100(4):1359-67
pubmed: 25636048
N Engl J Med. 1975 Feb 13;292(7):344-7
pubmed: 1090839
Rheumatology (Oxford). 2020 Aug 1;59(8):1862-1870
pubmed: 31740970
J Endocrinol. 2009 Jun;201(3):309-20
pubmed: 19443863
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S118-57
pubmed: 22588740
J Endocrinol Invest. 2011 Jul;34(7 Suppl):18-22
pubmed: 21985975
Scand J Rheumatol. 2008 Jan-Feb;37(1):40-7
pubmed: 18189194
Calcif Tissue Int. 2013 Apr;92(4):354-61
pubmed: 23247536
Arthritis Care Res (Hoboken). 2010 Aug;62(8):1103-11
pubmed: 20506141
Arthritis Rheum. 2004 Apr;50(4):1023-5
pubmed: 15077283
Semin Arthritis Rheum. 2020 Feb;50(1):149-155
pubmed: 31303436
Arthritis Rheum. 2003 Aug;48(8):2294-8
pubmed: 12905484
Rheumatology (Oxford). 2009 Dec;48(12):1541-7
pubmed: 19776224
Arthritis Care Res (Hoboken). 2012 Jan;64(1):122-31
pubmed: 22213727
J Musculoskelet Neuronal Interact. 2005 Jul-Sep;5(3):262-72
pubmed: 16172517
J Rheumatol. 2006 Aug;33(8):1642-5
pubmed: 16881120
Cell Signal. 2017 Jun;34:55-65
pubmed: 28302565
Arthritis Rheum. 2007 Jun;56(6):1966-73
pubmed: 17530722
Arthritis Rheumatol. 2019 Aug;71(8):1377-1390
pubmed: 30861625
Arthritis Rheum. 2003 Aug;48(8):2214-23
pubmed: 12905475
J Pediatr. 2012 Feb;160(2):297-302
pubmed: 21924736
Arthritis Rheum. 2012 Aug;64(8):2624-31
pubmed: 22487938
Arthritis Rheum. 2007 Mar;56(3):977-83
pubmed: 17328075
Int J Pediatr Endocrinol. 2019;2019:4
pubmed: 31889957
Nat Rev Rheumatol. 2011 Nov 01;7(12):708-17
pubmed: 22045310
Osteoporos Int. 2004 Jul;15(7):525-34
pubmed: 14966666
Braz J Med Biol Res. 2005 Feb;38(2):309-13
pubmed: 15785843
N Engl J Med. 2007 Jul 19;357(3):266-81
pubmed: 17634462
Ann Rheum Dis. 2011 Jan;70(1):86-91
pubmed: 20805295
Osteoporos Int. 2015 Feb;26(2):459-67
pubmed: 25146092
Arthritis Care Res (Hoboken). 2010 Jan 15;62(1):63-72
pubmed: 20191492
Arthritis Rheum. 2005 Jul;52(7):2051-9
pubmed: 15986346
Rheum Dis Clin North Am. 2012 Feb;38(1):45-59
pubmed: 22525842
Nat Rev Endocrinol. 2018 Nov;14(11):637-655
pubmed: 30218014
Ann Rheum Dis. 2013 Apr;72(4):512-6
pubmed: 22993226
Scand J Rheumatol. 2012 Feb;41(1):50-8
pubmed: 22044089
J Bone Miner Metab. 2000;18(6):350-2
pubmed: 11052469
J Rheumatol. 2005 Apr;32(4):729-33
pubmed: 15801032